EA020690B1 - Пиридазиноновые соединения - Google Patents

Пиридазиноновые соединения Download PDF

Info

Publication number
EA020690B1
EA020690B1 EA201171004A EA201171004A EA020690B1 EA 020690 B1 EA020690 B1 EA 020690B1 EA 201171004 A EA201171004 A EA 201171004A EA 201171004 A EA201171004 A EA 201171004A EA 020690 B1 EA020690 B1 EA 020690B1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
compound
mmol
phenyl
substituted
Prior art date
Application number
EA201171004A
Other languages
English (en)
Russian (ru)
Other versions
EA201171004A1 (ru
Inventor
Такахико Танигути
Акира Кавада
Мицуйо Кондо
Джон Ф. Куинн
Дзун Кунитомо
Масато Йосикава
Макото Фусими
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201171004A1 publication Critical patent/EA201171004A1/ru
Publication of EA020690B1 publication Critical patent/EA020690B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EA201171004A 2009-02-05 2010-02-04 Пиридазиноновые соединения EA020690B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20220709P 2009-02-05 2009-02-05
US21392709P 2009-07-30 2009-07-30
PCT/US2010/000307 WO2010090737A1 (en) 2009-02-05 2010-02-04 Pyridazinone compounds

Publications (2)

Publication Number Publication Date
EA201171004A1 EA201171004A1 (ru) 2012-03-30
EA020690B1 true EA020690B1 (ru) 2015-01-30

Family

ID=42398214

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171004A EA020690B1 (ru) 2009-02-05 2010-02-04 Пиридазиноновые соединения

Country Status (37)

Country Link
US (7) US8916566B2 (enExample)
EP (2) EP3006031A1 (enExample)
JP (1) JP5659166B2 (enExample)
KR (1) KR101730665B1 (enExample)
CN (1) CN102365020B (enExample)
AR (1) AR075238A1 (enExample)
AU (1) AU2010211050B2 (enExample)
BR (1) BRPI1008498B8 (enExample)
CA (1) CA2751565C (enExample)
CO (1) CO6410258A2 (enExample)
CR (1) CR20110440A (enExample)
DK (1) DK2393360T3 (enExample)
DO (1) DOP2011000254A (enExample)
EA (1) EA020690B1 (enExample)
EC (1) ECSP11011305A (enExample)
ES (1) ES2561181T3 (enExample)
GE (1) GEP20146004B (enExample)
HR (1) HRP20160065T1 (enExample)
HU (1) HUE027478T2 (enExample)
IL (1) IL214137A (enExample)
JO (1) JO3114B1 (enExample)
MA (1) MA33072B1 (enExample)
ME (1) ME02337B (enExample)
MX (1) MX2011008305A (enExample)
MY (1) MY170610A (enExample)
NZ (1) NZ594851A (enExample)
PE (1) PE20110991A1 (enExample)
PL (1) PL2393360T3 (enExample)
RS (1) RS54504B1 (enExample)
SG (1) SG173175A1 (enExample)
SI (1) SI2393360T1 (enExample)
SM (1) SMT201600008B (enExample)
TN (1) TN2011000362A1 (enExample)
TW (1) TWI457333B (enExample)
UY (1) UY32417A (enExample)
WO (1) WO2010090737A1 (enExample)
ZA (1) ZA201106074B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
JP5627574B2 (ja) * 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
ME02337B (me) * 2009-02-05 2016-06-20 Takeda Pharmaceuticals Co Jedinjenja piridazinona
WO2011163355A1 (en) 2010-06-24 2011-12-29 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
WO2012009194A1 (en) * 2010-07-12 2012-01-19 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
EP2601192B1 (en) 2010-08-04 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8883788B2 (en) 2010-08-04 2014-11-11 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
WO2012018059A1 (ja) 2010-08-04 2012-02-09 武田薬品工業株式会社 複素環化合物
EP2604597B1 (en) * 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
JP2013234123A (ja) * 2010-09-03 2013-11-21 Taisho Pharmaceutical Co Ltd ３−ピラゾリル−２−ピリドン誘導体
MX2013009575A (es) 2011-02-18 2014-10-14 Exonhit Therapeutics Sa Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
EP2687529B1 (en) 2011-03-16 2016-07-13 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JP6153513B2 (ja) * 2011-08-22 2017-06-28 武田薬品工業株式会社 哺乳類中のホスホジエステラーゼ（ｐｄｅ１０ａ）を定量的に画像化する放射性トレーサとしての放射標識された化合物及びその用途
US9212147B2 (en) 2011-11-15 2015-12-15 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
JP6364420B2 (ja) 2013-02-21 2018-07-25 武田薬品工業株式会社 ピリダジノン化合物の製造方法
WO2014142322A1 (ja) 2013-03-15 2014-09-18 第一三共株式会社 ベンゾチオフェン誘導体
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
HK1225382A1 (zh) * 2013-09-12 2017-09-08 Alios Biopharma, Inc. 噠嗪酮化合物及其用途
PE20160661A1 (es) 2013-09-12 2016-08-05 Alios Biopharma Inc Compuesto de azapiridona y sus usos de los mismos
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
ES2544869B2 (es) * 2014-03-04 2016-01-18 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
CN107428721B (zh) 2015-12-22 2020-07-28 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
US10736894B2 (en) 2018-02-15 2020-08-11 Ovid Therapeutics Inc. Methods of treating developmental syndromes with PDE10A inhibitors
CN108498868B (zh) * 2018-04-03 2020-09-15 北京大学口腔医学院 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
WO2019241787A1 (en) * 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
JP2022501335A (ja) * 2018-09-28 2022-01-06 武田薬品工業株式会社 自閉症スペクトラム障害を治療または予防するためのバリポデクト（Ｂａｌｉｐｏｄｅｃｔ）
MX2019008440A (es) 2019-07-15 2021-01-18 Dva Farma Mexicana S A De C V Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion.
EP3805206A1 (en) * 2019-10-08 2021-04-14 Novaled GmbH Compound and an organic semiconducting layer, an organic electronic device, a display device and a lighting device comprising the same
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877175A (en) * 1995-03-29 1999-03-02 Knoll Aktiengesellschaft Pharmaceutical compositions
US20040009988A1 (en) * 2000-06-01 2004-01-15 Nerina Dodic Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US20080207902A1 (en) * 2005-03-07 2008-08-28 Yasushi Kohno Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011693A1 (de) 1978-10-03 1980-06-11 Ciba-Geigy Ag Neue N-(trifluormethansulfonylaminophenyl)-substituierte N-Heterocyclen, ihre Herstellung, sie enthaltende Mittel und ihre Verwendung zur Beeinflussung des Pflanzenwachstums
FR2648135B1 (fr) * 1989-06-07 1991-09-27 Pf Medicament Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique
CA2340230C (en) 1998-08-14 2008-03-11 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives having cell adhesion inhibiting activity
ATE346064T1 (de) 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CA2568929A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
AU2005323794B2 (en) 2005-01-07 2012-07-19 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as PDE10 inhibitors
CA2654394A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
EP2373641B1 (en) * 2008-12-04 2012-12-19 F. Hoffmann-La Roche AG Pyridazinone derivatives
ME02337B (me) 2009-02-05 2016-06-20 Takeda Pharmaceuticals Co Jedinjenja piridazinona
US9187455B2 (en) 2009-02-23 2015-11-17 Hoffmann-La Roche Inc. Substituted pyridazines as PDE10A inhibitors
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US8883788B2 (en) * 2010-08-04 2014-11-11 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
EP2604597B1 (en) * 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877175A (en) * 1995-03-29 1999-03-02 Knoll Aktiengesellschaft Pharmaceutical compositions
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US20040009988A1 (en) * 2000-06-01 2004-01-15 Nerina Dodic Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors
US20080207902A1 (en) * 2005-03-07 2008-08-28 Yasushi Kohno Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient

Also Published As

Publication number Publication date
ME02337B (me) 2016-06-20
JO3114B1 (ar) 2017-09-20
US8354411B2 (en) 2013-01-15
CN102365020A (zh) 2012-02-29
PL2393360T3 (pl) 2016-04-29
US8435995B2 (en) 2013-05-07
US8916566B2 (en) 2014-12-23
US8513251B2 (en) 2013-08-20
DK2393360T3 (en) 2016-02-01
CO6410258A2 (es) 2012-03-30
EP2393360A4 (en) 2012-08-15
IL214137A0 (en) 2011-08-31
HUE027478T2 (en) 2016-09-28
AR075238A1 (es) 2011-03-16
PE20110991A1 (es) 2012-02-06
EP2393360A1 (en) 2011-12-14
US20100197651A1 (en) 2010-08-05
IL214137A (en) 2015-07-30
US20120277204A1 (en) 2012-11-01
MY170610A (en) 2019-08-20
GEP20146004B (en) 2014-01-10
US20120028951A1 (en) 2012-02-02
TN2011000362A1 (en) 2013-03-27
US20170114044A1 (en) 2017-04-27
BRPI1008498B8 (pt) 2021-05-25
TW201036958A (en) 2010-10-16
WO2010090737A1 (en) 2010-08-12
CN102365020B (zh) 2014-07-30
DOP2011000254A (es) 2011-09-30
UY32417A (es) 2010-08-31
US8778944B2 (en) 2014-07-15
EP2393360B1 (en) 2015-11-04
HRP20160065T1 (hr) 2016-02-12
MX2011008305A (es) 2012-08-15
CA2751565C (en) 2017-05-16
US20150099757A1 (en) 2015-04-09
CR20110440A (es) 2012-02-13
JP5659166B2 (ja) 2015-01-28
EA201171004A1 (ru) 2012-03-30
BRPI1008498B1 (pt) 2020-02-11
AU2010211050B2 (en) 2016-05-12
BRPI1008498A2 (pt) 2015-08-25
ES2561181T3 (es) 2016-02-24
SG173175A1 (en) 2011-09-29
US20120277430A1 (en) 2012-11-01
TWI457333B (zh) 2014-10-21
RS54504B1 (sr) 2016-06-30
AU2010211050A1 (en) 2011-09-08
MA33072B1 (fr) 2012-02-01
ZA201106074B (en) 2012-10-31
KR20110120931A (ko) 2011-11-04
JP2012516890A (ja) 2012-07-26
EP3006031A1 (en) 2016-04-13
KR101730665B1 (ko) 2017-04-26
CA2751565A1 (en) 2010-08-12
NZ594851A (en) 2013-10-25
US9550756B2 (en) 2017-01-24
ECSP11011305A (es) 2011-11-30
SMT201600008B (it) 2016-02-25
US20120277431A1 (en) 2012-11-01
AU2010211050A2 (en) 2011-10-06
HK1164642A1 (zh) 2012-09-28
SI2393360T1 (sl) 2016-02-29

Similar Documents

Publication Publication Date Title
EA020690B1 (ru) Пиридазиноновые соединения
EP2604597B1 (en) Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
CN107106561A (zh) 用于治疗疾病的硫酸乙酰肝素生物合成抑制剂
JP6762300B2 (ja) アミノピラゾール誘導体
HK1164642B (en) Pyridazinone compounds

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM